Difficulty: Medium
Average Score: 67%
Practice
Which of the following is not the criteria in the international prognostic index for non Hodgkin's lymphoma?
Correct answer
C
Rationale
In the context of Hematology drugs, understanding the criteria in the international prognostic index for non-Hodgkin's lymphoma is crucial for effective patient management. In this question, the correct answer is C) Lymphocyte count.
The international prognostic index for non-Hodgkin's lymphoma includes several key criteria to assess the prognosis of the disease. These criteria help oncologists determine the aggressiveness of the lymphoma and guide treatment decisions.
Lymphocyte count is not a criteria in the international prognostic index for non-Hodgkin's lymphoma because it primarily focuses on factors like the number of extranodal sites, LDH level (lactate dehydrogenase), and performance status. These factors are indicative of the extent of the disease, metabolic activity, and overall physical condition of the patient, which are crucial in predicting outcomes and tailoring treatment plans.
Understanding the correct criteria for prognostic assessment in non-Hodgkin's lymphoma is essential for healthcare professionals working in hematology/oncology. By knowing the right criteria, healthcare providers can make informed decisions regarding treatment strategies, monitor disease progression effectively, and provide better patient care.
The international prognostic index for non-Hodgkin's lymphoma includes several key criteria to assess the prognosis of the disease. These criteria help oncologists determine the aggressiveness of the lymphoma and guide treatment decisions.
Lymphocyte count is not a criteria in the international prognostic index for non-Hodgkin's lymphoma because it primarily focuses on factors like the number of extranodal sites, LDH level (lactate dehydrogenase), and performance status. These factors are indicative of the extent of the disease, metabolic activity, and overall physical condition of the patient, which are crucial in predicting outcomes and tailoring treatment plans.
Understanding the correct criteria for prognostic assessment in non-Hodgkin's lymphoma is essential for healthcare professionals working in hematology/oncology. By knowing the right criteria, healthcare providers can make informed decisions regarding treatment strategies, monitor disease progression effectively, and provide better patient care.